Written questions and answers

Written questions allow Members of Parliament to ask government ministers for information on the work, policy and activities of government departments.

Historical written answers can be found in Hansard.

Find the latest written questions and answers for the 2019-21 session below. We welcome your feedback on this service.

Show
by:
Find by:
Close

UIN

Unique Identifying Number – Every written question in the House of Commons has a UIN per Parliament. In the House of Lords each written questions has a UIN per parliamentary session.
Showing 1-20 out of 37
Results per page
Results per page 20 | 50 | 100
Expand all answers
Print selected
Q
Asked by Crispin Blunt
(Reigate)
[R]
Close

Registered Interest

Indicates that a relevant interest has been declared.

[N]
Close

Named Day

'Named day' questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.

Asked on: 18 May 2020
Home Office
Cannabis: Medical Treatments
Commons
To ask the Secretary of State for the Home Department, with reference to paragraphs 4 and 5 on page 3 of her Department's Factsheet on Cannabis, CBD and other cannabinoids, what assessment she has made of the limit of detection that is the appropriate level of sensitivity to accurately determine through laboratory analysis that there are no controlled cannabinoids present in a CBD product and that the product contains CBD in its pure form.
A
Answered by: Kit Malthouse
Answered on: 02 June 2020

The Department has made no assessment of limits of detection in relation to testing for the presence of controlled cannabinoids in CBD products. The Home Office approach is one of caution, that is, that a CBD product is likely to be controlled under the Misuse of Drugs Act 1971 and the Misuse of Drugs Regulations 2001 (‘the 2001 Regulations’) if it contains any controlled cannabinoids.

The term ‘administration’ in the exempt product definition is not defined by the 2001 Regulations. The Human Medicines Regulations 2012 provides the following as part of its definition:

““administer” means administer to a human being—

(a) orally, by injection, or by introduction into the body in any other way; or

(b) by external application (whether or not by direct application to the body)”

The interpretation of legislation is ultimately a matter for the courts to decide.

Grouped Questions: 48250
Q
Asked by Crispin Blunt
(Reigate)
[R]
Close

Registered Interest

Indicates that a relevant interest has been declared.

[N]
Close

Named Day

'Named day' questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.

Asked on: 18 May 2020
Home Office
Cannabis: Medical Treatments
Commons
To ask the Secretary of State for the Home Department, with reference to limb A of the definition of an exempted product on page five of her Department's Drug Licensing Factsheet - Cannabis, CBD and other cannabinoids, what her Department's definition is of the term administration.
A
Answered by: Kit Malthouse
Answered on: 02 June 2020

The Department has made no assessment of limits of detection in relation to testing for the presence of controlled cannabinoids in CBD products. The Home Office approach is one of caution, that is, that a CBD product is likely to be controlled under the Misuse of Drugs Act 1971 and the Misuse of Drugs Regulations 2001 (‘the 2001 Regulations’) if it contains any controlled cannabinoids.

The term ‘administration’ in the exempt product definition is not defined by the 2001 Regulations. The Human Medicines Regulations 2012 provides the following as part of its definition:

““administer” means administer to a human being—

(a) orally, by injection, or by introduction into the body in any other way; or

(b) by external application (whether or not by direct application to the body)”

The interpretation of legislation is ultimately a matter for the courts to decide.

Grouped Questions: 48249
Q
Asked by Crispin Blunt
(Reigate)
Asked on: 19 March 2020
Department of Health and Social Care
Health Services: Technology
Commons
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the implications for his policies on (a) improving access to innovative medicines and (b) fostering the life sciences sector of the National Institute for Health and Care Excellence health technology evaluation review.
A
Answered by: Jo Churchill
Answered on: 29 May 2020

The National Institute for Health and Care Excellence (NICE) is reviewing its methods for the development of technology appraisal and highly specialised technology recommendations in line with the commitment in the 2019 voluntary scheme for branded medicines pricing and access. The scheme also states the Government’s expectations for the review as follows: ‘“The Department expects that any future changes to NICE methods and processes would respond to the new types of innovation coming to the market, be consistent with improving the health gain achieved by spending on new innovative medicines, and support faster adoption of the most clinically and cost effective medicines.”’

Grouped Questions: 32039
Q
Asked by Crispin Blunt
(Reigate)
Asked on: 19 March 2020
Department of Health and Social Care
National Institute for Health and Care Excellence
Commons
To ask the Secretary of State for Health and Social Care, if he will support the National Institute for Health and Care Excellence to undertake its methods and processes in a way that (a) enables the attractiveness of the UK as a place to conduct clinical trials or supply human medicines and (b) enables that organisation to fulfil its statutory duty to promote innovation.
A
Answered by: Jo Churchill
Answered on: 29 May 2020

The National Institute for Health and Care Excellence (NICE) is reviewing its methods for the development of technology appraisal and highly specialised technology recommendations in line with the commitment in the 2019 voluntary scheme for branded medicines pricing and access. The scheme also states the Government’s expectations for the review as follows: ‘“The Department expects that any future changes to NICE methods and processes would respond to the new types of innovation coming to the market, be consistent with improving the health gain achieved by spending on new innovative medicines, and support faster adoption of the most clinically and cost effective medicines.”’

Grouped Questions: 32038
Q
Asked by Crispin Blunt
(Reigate)
Asked on: 19 March 2020
Department of Health and Social Care
Clinical Trials
Commons
To ask the Secretary of State for Health and Social Care, what guidance he has provided to regulatory and health authorities on ensuring that the UK remains an attractive place to conduct clinical trials and supply human medicines.
A
Answered by: Jo Churchill
Answered on: 29 May 2020

The Department is working directly with the Medicines and Healthcare products Regulatory Agency, Health Research Authority, NHS England and NHS Improvement, the National Institute for Health Research and other partners across the health and life sciences sectors to ensure that the United Kingdom remains an attractive place to conduct clinical trials and supply human medicines.

The Medicines and Medical Devices Bill provides the UK the means to remain a world-leading regulator and an important market for medicines and medical devices and supports the delivery of the Life Sciences Industrial Strategy to make the UK a leading global hub for life sciences. The Bill makes clear the importance of ensuring the UK is an attractive place to bring new products to market and conduct clinical trials, specifying that before making any regulations under the Bill, the Secretary of State must consider this point.

We are determined to maintain the UK’s position as one of the best locations globally to run clinical trials.

Q
Asked by Crispin Blunt
(Reigate)
[N]
Close

Named Day

'Named day' questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.

Asked on: 28 April 2020
Department of Health and Social Care
Coronavirus: LGBT People
Commons
To ask the Secretary of State for Health and Social Care, what assessment he has made of the health effects of the Covid-19 outbreak on (a) LGBT+ people and (b) other people with protected characteristics; and if he will make a statement.
A
Answered by: Ms Nadine Dorries
Answered on: 04 May 2020

The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.

Q
Asked by Crispin Blunt
(Reigate)
[N]
Close

Named Day

'Named day' questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.

Asked on: 28 April 2020
Ministry of Housing, Communities and Local Government
Homelessness: Coronavirus
Commons
To ask the Secretary of State for Housing, Communities and Local Government, how the specific needs of (a) LGBT+ homeless people and (b) other homeless people with protected characteristics have been taken into account in the steps the Government is taking to tackle the covid-19 outbreak.
A
Answered by: Luke Hall
Answered on: 04 May 2020

We have provided funding to assist local authorities to provide accommodation and support to vulnerable people who are at risk of, or who have been diagnosed with, coronavirus. This may include people identifying as LGBT+, as well as those who identify as having another protected characteristic.

£3.2 billion of additional funding was provided to local authorities to enable them to respond to Covid-19 pressures across the services they deliver. This is in addition to £3.2 million in targeted funding to ensure that we minimise the risk to those rough sleepers unable to self-isolate.

The Chancellor also announced a £750 million package of support for frontline charities across the UK. This will help charities to provide support to vulnerable people during the pandemic, including those whose beneficiaries have a protected characteristic.

Q
Asked by Crispin Blunt
(Reigate)
[N]
Close

Named Day

'Named day' questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.

Asked on: 29 April 2020
Foreign and Commonwealth Office
LGBT People: Human Rights
Commons
To ask the Secretary of State for Foreign and Commonwealth Affairs, how the Government is using its term as co-chair of the Equal Rights Coalition to ensure that LGBT+ people's rights are being upheld globally (a) during the covid-19 pandemic and (b) more generally.
A
Answered by: Wendy Morton
Answered on: 04 May 2020

As co-chair of the Equal Rights Coalition (ERC) in partnership with Argentina, we are leading the ERC's work, in co-operation with civil society, to address violence and discrimination against lesbian, gay, bisexual and transgender (LGBT) individuals, and the ongoing criminalisation of same sex conduct in 70 countries. We have started work on a new ERC Strategy to guide and re-energise the work of the ERC, and are currently working on an ERC statement that calls on all governments to limit the repercussions of the Covid-19 pandemic on people identified based on real or perceived sexual orientation, gender identity or sex characteristics. Likewise as Commonwealth Chair-in-Office, the UK continues to raise the importance of countering discrimination within the Commonwealth, including on grounds of gender identity or sexual orientation. In both of these roles working through international organisations, we regularly raise concerns about countries that do not comply with their human rights obligations and promote non-discrimination against LGBT people, including during the COVID-19 pandemic.

On 9 April, the UK participated in the UN Human Rights Council's first ever virtual conversation with the UN High Commissioner for Human Rights. Discussion focused on the human rights implications of the COVID-19 crisis which included concerns about increased risks on vulnerable groups. In his statement to the Council, our Ambassador to the UN in Geneva stressed the importance to ensure that parliaments, media and civil society all play their role to scrutinise the actions of governments and international agencies, and that we do not lose sight of the international human rights frameworks. The British Government remains committed to upholding the rights and freedoms of LGBT people in all circumstances.

Grouped Questions: 41367
Q
Asked by Crispin Blunt
(Reigate)
[N]
Close

Named Day

'Named day' questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.

Asked on: 29 April 2020
Foreign and Commonwealth Office
LGBT People: Coronavirus
Commons
To ask the Secretary of State for Foreign and Commonwealth Affairs, how his Department is using its term as (a) co-chair of the Equal Rights Coalition and (b) Commonwealth Chair in Office to ensure governments around the world are protecting LGBT+ communities from increased marginalisation and violence during the covid-19 pandemic.
A
Answered by: Wendy Morton
Answered on: 04 May 2020

As co-chair of the Equal Rights Coalition (ERC) in partnership with Argentina, we are leading the ERC's work, in co-operation with civil society, to address violence and discrimination against lesbian, gay, bisexual and transgender (LGBT) individuals, and the ongoing criminalisation of same sex conduct in 70 countries. We have started work on a new ERC Strategy to guide and re-energise the work of the ERC, and are currently working on an ERC statement that calls on all governments to limit the repercussions of the Covid-19 pandemic on people identified based on real or perceived sexual orientation, gender identity or sex characteristics. Likewise as Commonwealth Chair-in-Office, the UK continues to raise the importance of countering discrimination within the Commonwealth, including on grounds of gender identity or sexual orientation. In both of these roles working through international organisations, we regularly raise concerns about countries that do not comply with their human rights obligations and promote non-discrimination against LGBT people, including during the COVID-19 pandemic.

On 9 April, the UK participated in the UN Human Rights Council's first ever virtual conversation with the UN High Commissioner for Human Rights. Discussion focused on the human rights implications of the COVID-19 crisis which included concerns about increased risks on vulnerable groups. In his statement to the Council, our Ambassador to the UN in Geneva stressed the importance to ensure that parliaments, media and civil society all play their role to scrutinise the actions of governments and international agencies, and that we do not lose sight of the international human rights frameworks. The British Government remains committed to upholding the rights and freedoms of LGBT people in all circumstances.

Grouped Questions: 41366
Q
Asked by Crispin Blunt
(Reigate)
[N]
Close

Named Day

'Named day' questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.

Asked on: 29 April 2020
Foreign and Commonwealth Office
LGBT People: Coronavirus
Commons
To ask the Secretary of State for Foreign and Commonwealth Affairs, what steps he is taking to ensure that support for LGBT+ initiatives remain adequately resourced during the covid-19 pandemic.
A
Answered by: Wendy Morton
Answered on: 04 May 2020

The British Government is fundamentally opposed to all forms of discrimination and works to uphold the rights and freedoms of lesbian, gay, bisexual, transgender (LGBT) people in all circumstances, including during the COVID-19 pandemic. Funding for LGBT projects comes from a variety of sources. The Foreign and Commonwealth Office will consider future funding cycles for FCO funded programmes as part of its preparation for the Spending Review.

Q
Asked by Crispin Blunt
(Reigate)
[N]
Close

Named Day

'Named day' questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.

Asked on: 29 April 2020
Department for International Development
Overseas Aid: LGBT People
Commons
To ask the Secretary of State for International Development, what steps she is taking to ensure that support for LGBT+ initiatives are adequately resourced during the covid-19 outbreak.
A
Answered by: Wendy Morton
Answered on: 04 May 2020

Working on LGBT rights is essential to meet DFID’s vision of a world where no one is left behind. This is central to the Global Goals and a secure and prosperous world. Organisations implementing LGBT initiatives are facing significant challenges as a result of COVID-19. DFID supports many programmes on access to services for all, including vulnerable and persecuted minorities, promotion and protection of rights and tackling stigma and discrimination. These programmes include initiatives on LGBT inclusion. DFID is in discussion with partners to find flexible solutions to ensure they can use the resources allocated to implement these programmes effectively.

Q
Asked by Crispin Blunt
(Reigate)
[N]
Close

Named Day

'Named day' questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.

Asked on: 28 April 2020
Department for Education
Relationship and Sex Education
Commons
To ask the Secretary of State for Education, whether it remains his Department's policy that statutory relationships and sex education will be implemented in schools from September 2020.
A
Answered by: Nick Gibb
Answered on: 04 May 2020

The Department is giving due consideration to the implementation of the statutory relationships, sex and health education (RSHE) curriculum in the context of COVID-19. There is no intention to change the regulatory requirements for the implementation of RSHE.

The Department continues to work with key stakeholders and subject experts to develop a comprehensive programme of support for schools which includes a digital service to be delivered through GOV.UK.

Q
Asked by Crispin Blunt
(Reigate)
[N]
Close

Named Day

'Named day' questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.

Asked on: 28 April 2020
Department for International Development
Developing Countries: LGBT People
Commons
To ask the Secretary of State for International Development, what steps she is taking to ensure that the most vulnerable LGBTI+ people in developing countries (a) have fair and equal access and (b) receive non-discriminatory treatment in clinics and other healthcare settings in relation to (i) covid-19, (ii) hormone, (ii) antiretroviral, (iii) PrEP, (iv) PEP and (v) condom provision during the covid-19 pandemic.
A
Answered by: Wendy Morton
Answered on: 04 May 2020

The UK Government works to ensure that all aid reaches the most vulnerable including lesbian, gay, bisexual and transgender (LGBT) people. Vulnerable populations will experience COVID 19 outbreaks differently. COVID 19 is likely to reinforce their marginalised position in society, their experience of discrimination, violence and stigma, and further limit their access to essential support and services. For this reason, on 9 April, further guidance was circulated across DFID highlighting that inclusion must be central to our response to COVID 19 and the specific contexts and needs of vulnerable people such as LGBT people should be taken into account when developing practical programmes to tackle COVID 19.

Q
Asked by Crispin Blunt
(Reigate)
Asked on: 19 March 2020
Department of Health and Social Care
Cancer: Drugs
Commons
To ask the Secretary of State for Health and Social Care, what Cancer Drugs Fund expenditure cap is for (a) 2019-20 and (b) 2020-21.
A
Answered by: Jo Churchill
Answered on: 27 April 2020

The Government established the Cancer Drugs Fund (CDF) to ensure access for National Health Service patients in England to effective cancer drugs that would not otherwise have been available to them. New arrangements for the assessment and adoption of new cancer drugs were introduced in 2016 to help improve patient access to new cancer drugs and the CDF is now linked to the National Institute for Health and Care Excellence (NICE) technology appraisal programme.

Under the new arrangements, NICE now appraises all new cancer drugs, and NICE is able to recommend a drug for use through the CDF where there is too much uncertainty to be able to recommend routine use. All cancer drugs recommended by NICE are eligible for funding through the CDF from the point of NICE’s draft guidance.

Since it was reformed in July 2016, the CDF has had a fixed budget of £340 million. This will remain the same for 2020-21.

Grouped Questions: 32029
Q
Asked by Crispin Blunt
(Reigate)
Asked on: 19 March 2020
Department of Health and Social Care
Cancer: Drugs
Commons
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the reasons why the Cancer Drugs Fund has been underspent; and if he will make a statement.
A
Answered by: Jo Churchill
Answered on: 27 April 2020

The Government established the Cancer Drugs Fund (CDF) to ensure access for National Health Service patients in England to effective cancer drugs that would not otherwise have been available to them. New arrangements for the assessment and adoption of new cancer drugs were introduced in 2016 to help improve patient access to new cancer drugs and the CDF is now linked to the National Institute for Health and Care Excellence (NICE) technology appraisal programme.

Under the new arrangements, NICE now appraises all new cancer drugs, and NICE is able to recommend a drug for use through the CDF where there is too much uncertainty to be able to recommend routine use. All cancer drugs recommended by NICE are eligible for funding through the CDF from the point of NICE’s draft guidance.

Since it was reformed in July 2016, the CDF has had a fixed budget of £340 million. This will remain the same for 2020-21.

Grouped Questions: 32028
Q
Asked by Crispin Blunt
(Reigate)
Asked on: 19 March 2020
Department of Health and Social Care
NHS: Drugs
Commons
To ask the Secretary of State for Health and Social Care, which medicinal products were made available on the NHS with a managed access agreement in (a) 2018-19 and (b) 2019 to date.
A
Answered by: Jo Churchill
Answered on: 27 April 2020

The National Institute for Health and Care Excellence (NICE) has recommended 11 topics for access via a Managed Access Agreement (MAA) in 2019/20 to date. In 2018/19, 12 topics were recommended via an MAA.

These topics are listed in the following table.

NICE ref

Drug

Indication

Managed access start date

2018/19

TA522

Pembrolizumab

locally advanced or metastatic urothelial cancer where cisplatin is unsuitable

27 April 2018

TA529

Crizotinib

ROS1-positive advanced non-small-cell lung cancer

31 May 2018

TA528

Niraparib

platinum-sensitive ovarian cancer after second response to chemotherapy

1 June 2018

TA540

Pembrolizumab

Relapsed or refractory classical Hodgkin lymphoma

25 July 2018

TA554

Tisagenlecleucel

relapsed or refractory B-cell acute lymphoblastic leukaemia

16 November 2018

TA553

Pembrolizumab

adjuvant treatment of resected melanoma with high risk of recurrence

19 November 2018

TA557

Pembrolizumab (with pemetrexed and platinum chemotherapy)

untreated metastatic non-squamous NSCLC

21 November 2018

TA558

Nivolumab

adjuvant treatment of resected stage III and IV melanoma

30 November 2018

TA559

Axicabtagene ciloleucel

diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma after 2 or more systemic therapies

7 December 2018

TA567

Tisagenlecleucel

relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies

1 February 2019

TA573

Daratumumab with bortezomib

Multiple myeloma

12 March 2019

TA578

Durvalumab

NSCLC

28 March 2019

2019/2020

TA579

Abemaciclib with fulvestrant

HER2-negative breast cancer after endocrine therapy

2 April 2019

TA581

Nivolumab with ipilimumab

untreated advanced renal cell carcinoma

5 April 2019

TA592

Cemiplimab

cutaneous squamous cell carcinoma

2 July 2019

TA588

Nusinersen

Spinal Muscular Atrophy

3 July 2019

TA593

Ribociclib

in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative breast cancer

17 July 2019

TA598

Olaparib

maintenance treatment of newly diagnosed BRCA-mutated advanced ovarian, fallopian tube or peritoneal cancer, after response to first-line platinum-based chemotherapy

26 July 2019

TA600

Pembrolizumab with carboplatin and paclitaxel

Metastatic squamous NSCLC

8 August 2019

TA611

Rucaparib

maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer

11 October 2019

TA619

Palbociclib in combination with fulvestrant

advanced, HR+ HER2- breast cancer after endocrine therapy

28 November 2019

TA620

Olaparib

maintenance treatment of BRCA-mutated platinum sensitive relapsed ovarian, fallopian tube and peritoneal cancer, after response to platinum-based chemotherapy

29 November 2019

HST12

Cerliponase alfa

neuronal ceroid lipofuscinosis type 2

5 November 2019

Q
Asked by Crispin Blunt
(Reigate)
Asked on: 19 March 2020
Department of Health and Social Care
NHS: Drugs
Commons
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential effect of the NHS Commercial Framework on access to medicines through managed access agreements.
A
Answered by: Jo Churchill
Answered on: 27 April 2020

NHS England and NHS Improvement has advised that the Commercial Framework for new medicines remains in draft at this time with publication expected in spring 2020. The Commercial Framework is designed to complement the processes and methods of the National Institute for Health and Care Excellence’s technology appraisal programme which provides direction on when managed access agreements may be appropriate. The framework will promote the opportunities that currently exist and clarify NHS England and NHS Improvement’s involvement within the existing arrangements rather than advising on new opportunities for managed access agreements.

Q
Asked by Crispin Blunt
(Reigate)
Asked on: 19 March 2020
Department of Health and Social Care
Medical Treatments: Innovation
Commons
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 26 February 2020 to Question 18744 on Medical Treatments: Innovation,whether he plans to hold a public consultation on his proposals for an innovative medicines fund.
A
Answered by: Jo Churchill
Answered on: 27 April 2020

Detailed proposals for the new Innovative Medicines Fund are in development and will be consulted on in due course. The Fund will build on the success of the reformed Cancer Drugs Fund so that doctors can use the most advanced, life-saving treatments for conditions such as autoimmune disease or cancer, or for children with other rare diseases.

Grouped Questions: 32033
Q
Asked by Crispin Blunt
(Reigate)
Asked on: 19 March 2020
Department of Health and Social Care
Rare Diseases: Drugs
Commons
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 26 February 2020 to Question 18743 on Medical Treatments: Innovation, if he will include provisions on improving access to medicine for rare diseases as part of the innovative medicines fund.
A
Answered by: Jo Churchill
Answered on: 27 April 2020

Detailed proposals for the new Innovative Medicines Fund are in development and will be consulted on in due course. The Fund will build on the success of the reformed Cancer Drugs Fund so that doctors can use the most advanced, life-saving treatments for conditions such as autoimmune disease or cancer, or for children with other rare diseases.

Grouped Questions: 32032
Q
Asked by Crispin Blunt
(Reigate)
Asked on: 19 March 2020
Department of Health and Social Care
NHS: Drugs
Commons
To ask the Secretary of State for Health and Social Care, with reference to paragraph 3.21 of the 2019 voluntary scheme for branded medicines pricing and access, when NICE will review the process and methods for the highly specialised technology evaluation programme; and what methodology will be used in that review.
A
Answered by: Jo Churchill
Answered on: 27 April 2020

The National Institute for Health and Care Excellence (NICE) has now initiated the review of its technology appraisal and highly specialised technologies methods in line with the commitment made in the 2019 Voluntary Scheme for Branded Medicines Pricing and Access. Further information about the process and timescale for the review is available on the NICE website at the following link:

https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance/changes-to-health-technology-evaluation

Expand all answers
Print selected
Showing 1-20 out of 37
Results per page
Results per page 20 | 50 | 100